-
Triglyceride-glucose index predicts future metabolic syndrome in an adult population, Korea: a prospective cohort study
-
Min-Su Park
-
Ann Clin Nutr Metab 2024;16(3):168-172. Published online December 1, 2024
-
DOI: https://doi.org/10.15747/ACNM.2024.16.3.168
-
-
 Abstract
 PDF
- Purpose: The triglyceride-glucose (TyG) index has been proposed as a reliable surrogate marker for insulin resistance. This study aimed to assess the utility of the TyG index in predicting the future presence of metabolic syndrome (MetS) in an adult population.
Methods: A total of 3,241 adults aged 40–70 years were included in this cross-sectional study. MetS was diagnosed based on the modified National Cholesterol Education Program Adult Treatment Panel III criteria, which requires the presence of at least three of the following components: abdominal obesity, elevated blood pressure, dysglycemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol.
Results: In comparison to the homeostasis model assessment of insulin resistance (HOMA-IR), the TyG index exhibited superior diagnostic performance, with a higher area under the receiver operating characteristic curve of 0.854 vs. 0.702 for HOMA-IR. The 95% confidence interval for the TyG index was narrower, reflecting a more consistent predictive ability. Sensitivity for the TyG index was 79.7%, while specificity was 79.3%, compared to HOMA-IR, which showed a sensitivity of 52.7% and specificity of 78.3%.
Conclusion: The TyG index is a highly effective and robust tool for identifying individuals at risk for MetS, demonstrating superior sensitivity and predictive accuracy over HOMA-IR. This index could be a valuable clinical marker for early detection of MetS, aiding in the prevention and management of associated metabolic disorders.
-
Relationship of Sarcopenia with the Outcomes of Patients who Underwent Surgery for Bile Duct Cancer
-
Hye Jin Kim, Min-Su Park, Bum-Soo Kim, Sang-Mok Lee
-
Surg Metab Nutr 2019;10(2):54-58. Published online December 30, 2019
-
DOI: https://doi.org/10.18858/smn.2019.10.2.54
-
-
Abstract
PDF
Purpose:This study investigated the impact of Sarcopenia by examining the psoas muscle on the outcomes after bile duct resection for bile duct cancer. Materials and Methods:This study retrospectively analyzed 101 patients who underwent surgery for bile duct cancer between January 2006 and December 2015 at Kyung-Hee University Hospital. Skeletal muscle mass was evaluated by performing preoperative computed tomography to define Sarcopenia. Patients were classified into two groups by the median value of the psoas muscle index (PMI). Results:The median value of the psoas muscle index in female patients was 463.9 mm2/m2, and the median value of the psoas muscle index in males was 688.7 mm2/m2. In the sarcopenia group, the 1, 3, and 5-year recurrence free survival rates were 74.5%, 52.9%, and 27.5%, respectively. On the other hand, in the non-sarcopenia group the 1, 3, and 5-year recurrence free survival rates were 50%, 34%, and 28%, respectively. In the sarcopenia group, the 1, 3, and 5-year overall survival rates were 84.3%, 54.9%, and 31.4%, respectively. In the non-sarcopenia group, 1, 3, and 5-year overall survival rates were 58%, 40%, and 32%, respectively. However, recurrence-free survival and overall survival were not correlated with sarcopenia (P=0.131, P=0.163). Conclusion:Sarcopenia using the psoas muscle index (PMI) has no impact on outcomes of bile duct cancer patients who underwent surgery. (Surg Metab Nutr 2019;10:-58)
|
KSPEN
KSSMN
ASSMN
